

References

Y-5068

1. Saiyin T, Kirkham AM, Bailey AJM, et al. Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies. *Transplant Cell Ther.* Feb 2023; 29(2): 129.e1-129.e9. PMID 36396108
2. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. *J Clin Invest.* Jul 2014; 124(7): 3121-8. PMID 24911148
3. Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. *Blood.* Oct 21 2021; 138(16): 1429-1440. PMID 34157093
4. Horwitz ME, Wease S, Blackwell B, et al. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. *J Clin Oncol.* Feb 10 2019; 37(5): 367-374. PMID 30523748
5. Anand S, Thomas S, Hyslop T, et al. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. *Biol Blood Marrow Transplant.* Jul 2017; 23(7): 1151-1157. PMID 28392378
6. Food and Drug Administration (FDA). Omisirge (Omidubicel) BLA Clinical Review Memorandum. April 14, 2023. <https://www.fda.gov/media/168098/download>. Accessed August 8, 2023.
7. Lin C, Sajeew G, Stiff PJ, et al. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood. *Transplant Cell Ther.* Jan 2023; 29(1): 52.e1-52.e9. PMID 36179986
8. Shearer WT, Lubin BH, Cairo MS, et al. Cord Blood Banking for Potential Future Transplantation. *Pediatrics.* Nov 2017; 140(5). PMID 29084832
9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute Lymphoblastic Leukemia. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed June 23, 2023.
10. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute Myeloid Leukemia. Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed June 24, 2023.
11. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: B-Cell Lymphomas. Version 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed June 25, 2023.
12. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Chronic Myeloid Leukemia. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed June 26, 2023.
13. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hematopoietic Cell Transplantation (HCT). Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf. Accessed June 27, 2023.
14. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hodgkin Lymphoma. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed June 28, 2023.
15. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Myelodysplastic Syndromes. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed June 29, 2023.
16. Kanate AS, Majhail NS, Savani BN, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* Jul 2020; 26(7): 1247-1256. PMID 32165328